Evaluating haemodynamic changes: vericiguat in patients with heart failure with reduced ejection fraction

• DOI: 10.1002/ehf2.14802
• Publication Date: 2024-04-30T04:45:09Z
• Authors: Hideaki Suzuki; Takumi Inoue; Yousuke Terui; Kouki Takeuchi; Kai Susukita; Marina Arai; Haruka Sato; Taijyu Satoh; Saori Yamamoto; Nobuhiro Yaoita; Shunsuke Tatebe; Hideka Hayashi; Kotaro Nochioka; Hiroyuki Takahama; Satoshi Yasuda
• Keywords: Fraction (chemistry)

Vericiguat has been used to treat patients with heart failure reduced ejection fraction (HFrEF) who demonstrated worsening despite treatment other guideline-directed medical therapies. The haemodynamic effects of vericiguat remain unclear.